David Lafon

Dr. David Lafon


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2024 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
KOKristopher Opron
Kristopher Opron
LBLesa A. Begley
Lesa A. Begley
JEJohn R. Erb-Downward
John R. Erb-Downward
GLGen Li
Gen Li
NANeil E. Alexis
Neil E. Alexis
YHYvonne Huang
Yvonne Huang
Rationale: The airway microbiome has the potential to shape chronic obstructive pulmonary disease (COPD) pathogenesis, but its relationship to outcomes in milder disease is unestablished. Objectives: To identify sputum microbiome characteristics associated with markers of COPD in participants of the Subpopulations and Intermediate Outcome Measures of COPD Study (SPIROMICS). Methods: Sputum DNA from 877 participants was analyzed using 16S ribosomal RNA gene sequencing. Relationships between baseline airway microbiota composition and clinical, radiographic, and mucoinflammatory markers, including longitudinal lung function trajectory, were examined. Measurements and Main Results: Participant data represented predominantly milder disease (Global Initiative for Chronic Obstructive Lung Disease stage 0–2 obstruction in 732 of 877 participants). Phylogenetic diversity (i.e., range of different species within a sample) correlated positively with baseline lung function, decreased with higher Global Initiative for Chronic Obstructive Lung Disease stage, and correlated negatively with symptom burden, radiographic markers of airway disease, and total mucin concentrations (P < 0.001). In covariate-adjusted regression models, organisms robustly associated with better lung function included Alloprevotella, Oribacterium, and Veillonella species. Conversely, lower lung function, greater symptoms, and radiographic measures of small airway disease were associated with enrichment in members of Streptococcus, Actinobacillus, Actinomyces, and other genera. Baseline sputum microbiota features were also associated with lung function trajectory during SPIROMICS follow-up (stable/improved, decline, or rapid decline groups). The stable/improved group (slope of FEV1 regression ⩾66th percentile) had greater bacterial diversity at baseline associated with enrichment in Prevotella, Leptotrichia, and Neisseria species. In contrast, the rapid decline group (FEV1 slope ⩽33rd percentile) had significantly lower baseline diversity associated with enrichment in Streptococcus species. Conclusions: In SPIROMICS, baseline airway microbiota features demonstrate divergent associations with better or worse COPD-related outcomes.

1 February 2020 in Vaccine
Verified
Journal Article
Closed access
SSSarah Sterrett
Sarah Sterrett
BPBinghao J. Peng
Binghao J. Peng
RBRobert L. Burton
Robert L. Burton
DLDavid Lafon
David Lafon
AWAndrew O. Westfall
Andrew O. Westfall
ABAnju Bansal
Anju Bansal

1 January 2016 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
YKYoung Keun Kim
Young Keun Kim
DLDavid Lafon
David Lafon
MNMoon H. Nahm
Moon H. Nahm
Kim YK, et al. Infect Chemother. 2016 Dec;48(4):257-266. https://doi.org/10.3947/ic.2016.48.4.257

26 November 2019 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
DLDavid Lafon
David Lafon
SBSurya P. Bhatt
Surya P. Bhatt
WLWassim W. Labaki
Wassim W. Labaki
FRFarbod N. Rahaghi
Farbod N. Rahaghi
MMMatthew Moll
Matthew Moll
JWJ. Michael Wells
J. Michael Wells
Pulmonary artery enlargement on chest CT imaging is independently associated with all-cause mortality in moderate–severe COPD, after adjustment for other known risk factors for COPD mortality and cardiovascular disease http://bit.ly/2rdYOR1

1 May 2021 in Annals of the American Thoracic Society
Verified
Journal Article
Open access
MDMark T Dransfield
Mark T Dransfield
CCCourtney Crim
Courtney Crim
GCGerard J. Criner
Gerard J. Criner
NDNicola C Day
Nicola C Day
DHDavid M G Halpin
David M G Halpin
PLPeter Lange
Peter Lange
Rationale: In the IMPACT (Informing the Pathway of COPD Treatment) trial, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy reduced exacerbation risk versus FF/VI and UMEC/VI and mortality risk versus UMEC/VI. However, pneumonia incidence was higher in the inhaled corticosteroid (FF)–containing arms, raising questions about the relative benefit of exacerbation reduction compared with the increased risk of pneumonia. Objectives: Determine benefit–risk of the three treatments by evaluating time-to-first and rates of composite exacerbation or pneumonia outcomes. Methods: We evaluated time-to-first (prespecified) and rates (post hoc) of investigator-reported pneumonia, serious pneumonia leading to hospitalization or death, and the composite endpoints of 1) moderate (required antibiotics/corticosteroids)/severe (hospitalized) exacerbation or pneumonia and 2) severe exacerbation or serious (hospitalized) pneumonia. Analyses were repeated for radiographically confirmed pneumonia (post hoc). Results: Moderate/severe exacerbations occurred in 47%, 49%, and 50% of patients randomized to FF/UMEC/VI, FF/VI and UMEC/VI, and pneumonias in 8%, 7%, and 5%, respectively. FF/UMEC/VI reduced the risk of combined moderate/severe exacerbation or pneumonia (time-to-first) versus FF/VI (hazard ratio, 0.87 [95% confidence interval (CI), 0.82–0.92]) and UMEC/VI (0.87 [0.81–0.94]), as well as the risk of combined severe exacerbation or serious pneumonia versus UMEC/VI (0.83 [0.72–0.96]). FF/UMEC/VI reduced the rate of combined moderate/severe exacerbation or pneumonia (rate ratio, 0.78 [0.72–0.84]) and combined severe exacerbation or serious pneumonia (rate ratio, 0.76 [0.65–0.89]) versus UMEC/VI. Results were similar for radiographically confirmed pneumonia endpoints. Conclusions: Despite higher incidence of pneumonia in FF-containing arms, these composite exacerbation/pneumonia outcomes support a favorable benefit–risk profile of FF/UMEC/VI versus FF/VI and UMEC/VI in patients with symptomatic chronic obstructive pulmonary disease and a history of exacerbations.

1 February 2025 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
MBMichael Burnim
Michael Burnim
NPNirupama Putcha
Nirupama Putcha
DLDavid Lafon
David Lafon
HWHan Woo
Han Woo
AAAntoine E. Azar
Antoine E. Azar
NHNadia Hansel
Nadia Hansel
Rationale: Serum IgG deficiency is associated with morbidity in chronic obstructive pulmonary disease (COPD), but it is unclear whether concentrations in the lower end of the normal range still confer risk. Objectives: To determine if levels above traditional cutoffs for serum IgG deficiency are associated with exacerbations among current and former smokers with or at risk for COPD. Methods: Former and current smokers in SPIROMICS (the Subpopulations and Intermediate Outcome Measures of COPD study) (n = 1,497) were studied: 1,026 with COPD and 471 at risk for COPD. In a subset (n = 1,031), IgG subclasses were measured. Associations between total IgG or subclasses and prospective exacerbations were evaluated with multivariable models adjusting for demographic characteristics, current smoking, smoking history, FEV1 percent predicted, inhaled corticosteroids, and serum IgA. Measurements and Main Results: The 35th percentile (1,225 mg/dl in this cohort) of IgG was the best cutoff by Akaike information criterion. Below this, there was increased exacerbation risk (incidence rate ratio [IRR], 1.28; 95% confidence interval [CI], 1.08–1.51). Among subclasses, IgG1 and IgG2 below the 35th percentile (354 and 105 mg/dl, respectively) were associated with increased risks of severe exacerbation (IgG1, IRR, 1.39; 95% CI, 1.06–1.84; IgG2, IRR, 1.50; 95% CI, 1.14–1.1.97). These associations remained significant when additionally adjusting for a history of exacerbations. Conclusions: Lower serum IgG is prospectively associated with exacerbations in individuals with or at risk for COPD. Among subclasses, lower IgG1 and IgG2 are prospectively associated with severe exacerbations. The optimal IgG cutoff was substantially higher than traditional cutoffs for deficiency, suggesting that subtle impairment of humoral immunity may be associated with exacerbations.